JP2018512379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512379A5 JP2018512379A5 JP2017542004A JP2017542004A JP2018512379A5 JP 2018512379 A5 JP2018512379 A5 JP 2018512379A5 JP 2017542004 A JP2017542004 A JP 2017542004A JP 2017542004 A JP2017542004 A JP 2017542004A JP 2018512379 A5 JP2018512379 A5 JP 2018512379A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101001128739 Homo sapiens Nucleoside diphosphate kinase 6 Proteins 0.000 claims 1
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims 1
- 101000773116 Homo sapiens Thioredoxin domain-containing protein 3 Proteins 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100032113 Nucleoside diphosphate kinase 6 Human genes 0.000 claims 1
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims 1
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102100030271 Thioredoxin domain-containing protein 3 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021021535A JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2023124894A JP2023162180A (ja) | 2015-02-10 | 2023-07-31 | ヒト化抗ｍｕｃ１＊抗体 |
| JP2025091489A JP2025148326A (ja) | 2015-02-10 | 2025-05-30 | ヒト化抗ｍｕｃ１＊抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114526P | 2015-02-10 | 2015-02-10 | |
| US62/114,526 | 2015-02-10 | ||
| PCT/US2016/017422 WO2016130726A1 (en) | 2015-02-10 | 2016-02-10 | Humanized anti-muc1* antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021021535A Division JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512379A JP2018512379A (ja) | 2018-05-17 |
| JP2018512379A5 true JP2018512379A5 (OSRAM) | 2019-03-14 |
| JP6895890B2 JP6895890B2 (ja) | 2021-06-30 |
Family
ID=56615670
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542004A Active JP6895890B2 (ja) | 2015-02-10 | 2016-02-10 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2021021535A Active JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2023124894A Pending JP2023162180A (ja) | 2015-02-10 | 2023-07-31 | ヒト化抗ｍｕｃ１＊抗体 |
| JP2025091489A Pending JP2025148326A (ja) | 2015-02-10 | 2025-05-30 | ヒト化抗ｍｕｃ１＊抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021021535A Active JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2023124894A Pending JP2023162180A (ja) | 2015-02-10 | 2023-07-31 | ヒト化抗ｍｕｃ１＊抗体 |
| JP2025091489A Pending JP2025148326A (ja) | 2015-02-10 | 2025-05-30 | ヒト化抗ｍｕｃ１＊抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11746159B2 (OSRAM) |
| EP (1) | EP3256494A4 (OSRAM) |
| JP (4) | JP6895890B2 (OSRAM) |
| CN (2) | CN107660213B (OSRAM) |
| AU (3) | AU2016219350A1 (OSRAM) |
| CA (1) | CA2976089A1 (OSRAM) |
| IL (1) | IL253909B (OSRAM) |
| WO (1) | WO2016130726A1 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102239182B (zh) * | 2008-10-06 | 2014-07-09 | 米纳瓦生物技术公司 | Muc1*抗体 |
| KR20210107166A (ko) | 2014-04-07 | 2021-08-31 | 미네르바 바이오테크놀로지 코포레이션 | 항-ｎｍｅ 항체 |
| AU2016219350A1 (en) | 2015-02-10 | 2017-08-24 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
| EP3525804A4 (en) * | 2016-10-11 | 2020-09-09 | Minerva Biotechnologies Corporation | HUMANIZED ANTI-MUC1 * ANTIBODIES AND USE OF THE CLIVING ENZYME |
| CN108003237B (zh) * | 2016-11-01 | 2023-03-10 | 中国科学院广州生物医药与健康研究院 | 高稳定性的人源化抗人cd3单链抗体及其制法和应用 |
| TWI780082B (zh) * | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| CN110300603B (zh) * | 2017-02-14 | 2023-04-14 | 亘喜生物科技（上海）有限公司 | Cd47-car-t细胞 |
| CN109797171A (zh) * | 2017-05-08 | 2019-05-24 | 北京东方略细胞技术有限公司 | 经修饰的t细胞、其制备方法及用途 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| KR20200085780A (ko) * | 2017-11-07 | 2020-07-15 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화 |
| US20200390870A1 (en) * | 2017-11-27 | 2020-12-17 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| US11976132B2 (en) * | 2018-02-26 | 2024-05-07 | Minerva Biotechnologies Corporation | Diagnostic methods using anti-MUC1* antibodies |
| US20200405832A1 (en) * | 2018-03-09 | 2020-12-31 | Minerva Biotechnologies Corporation | Method for anti-muc1* car t cell stimulation |
| CA3100317A1 (en) | 2018-05-17 | 2019-11-21 | Astellas Pharma Inc. | Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand |
| CA3115747A1 (en) | 2018-10-10 | 2020-04-16 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| WO2020088164A1 (zh) | 2018-11-01 | 2020-05-07 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
| CN120484122A (zh) * | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN113646332B (zh) * | 2019-03-15 | 2024-08-23 | 公益财团法人癌研究会 | 抗平足蛋白抗体 |
| AU2020268372A1 (en) * | 2019-05-07 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| CA3140393A1 (en) * | 2019-06-04 | 2020-12-10 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| JP2022538008A (ja) * | 2019-06-26 | 2022-08-31 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫エフェクター細胞をターゲット化して増殖させるための方法及び材料 |
| KR20220034133A (ko) * | 2019-06-26 | 2022-03-17 | 더 존스 홉킨스 유니버시티 | 조절 t 세포의 표적화된 확장을 위한 방법 및 재료 |
| US20220291233A1 (en) * | 2019-07-19 | 2022-09-15 | Universiteit Antwerpen | Mucin isoforms in diseases characterized by barrier dysfunction |
| KR20230021699A (ko) * | 2020-06-08 | 2023-02-14 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| IL298510A (en) | 2020-06-12 | 2023-01-01 | Nkarta Inc | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| WO2021263227A2 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| CN116234828A (zh) * | 2020-07-29 | 2023-06-06 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| KR20240082383A (ko) * | 2021-09-29 | 2024-06-10 | 키소지 바이오테크놀로지 인코포레이티드 | Trop2를 발현하는 종양 세포를 표적으로 하는 결합제 |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| IL316918A (en) * | 2022-05-09 | 2025-01-01 | Minerva Biotechnologies Corp | Chimeric antigen receptor and IL-18 receptor compositions and methods of using them |
| US20240261406A1 (en) * | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| EP4619421A2 (en) * | 2023-05-01 | 2025-09-24 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Mutant interleukin 15 expressing immune cells |
| WO2025250739A1 (en) * | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Chimeric antigen receptor with spacer domains derived from human igg |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5108933A (en) | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
| EP0369816A3 (en) | 1988-11-17 | 1990-09-12 | The University Of Melbourne | Monoclonal antibodies specific for human polymorphic epithelial mucin |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| EP0505566A1 (en) | 1989-12-15 | 1992-09-30 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| IL110464A0 (en) | 1994-07-26 | 1994-10-21 | Univ Ramot | Novel proteins for the diagnosis, imaging, and therapy of human cancer |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6127393A (en) | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US5767135A (en) | 1995-12-29 | 1998-06-16 | Fernandez-Pol; Jose Alberto | Antiviral agent |
| US20020136725A1 (en) | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| FR2746016B1 (fr) | 1996-03-15 | 1998-04-17 | Combinaisons d'enzymes pour la destruction de cellules proliferatives | |
| CN1248731C (zh) | 1997-02-18 | 2006-04-05 | 坎吉公司 | 肿瘤抑制基因与化学药物在制备用于治疗肿瘤的药物组合物中的联合应用 |
| TWI242563B (en) | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
| DE69941031D1 (de) | 1998-11-12 | 2009-08-06 | Novolytics Inc | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion |
| EP1137938A4 (en) | 1998-12-08 | 2003-03-19 | Smithkline Beecham Corp | METHODS FOR DETECTION OF HDPXU17 RECEPTOR AGONISTS AND ANTAGONISTS |
| WO2000043783A2 (en) | 1999-01-23 | 2000-07-27 | Minerva Biotechnologies Corporation | Assays involving colloids and non-colloidal structures |
| CA2361013A1 (en) | 1999-01-25 | 2000-07-27 | Minerva Biotechnologies Corporation | Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| KR20020060736A (ko) | 1999-11-12 | 2002-07-18 | 추후보정 | 세포내 말로닐 조효소 에이의 수준을 증가시킴에 의한암의 치료 방법 |
| DE60140461D1 (de) | 2000-09-11 | 2009-12-24 | Genzyme Corp | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren |
| AU2002248909A1 (en) | 2000-11-15 | 2002-05-27 | Minerva Biotechnologies Corporation | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| JP4564714B2 (ja) | 2000-11-27 | 2010-10-20 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
| US20050019324A1 (en) | 2001-03-29 | 2005-01-27 | Wreschner Daniel H. | Peptides and antibodies to muc 1 proteins |
| US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
| EP2116248A1 (en) | 2001-09-05 | 2009-11-11 | Minerva Biotechnologies Corporation | Compositions and Methods of Treatment of Cancer |
| CA2459584A1 (en) | 2001-09-05 | 2003-03-13 | Cynthia C. Bamdad | Compositions and use thereof in the treatment of cancer |
| US6716627B2 (en) | 2001-12-20 | 2004-04-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of mucin 1, transmembrane expression |
| EP1483295B1 (en) | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
| EP1497649A4 (en) | 2002-04-22 | 2006-03-22 | Dyax Corp | FOR MUCIN POLYPEPTIDE SPECIFIC ANTIBODIES |
| AU2003234274A1 (en) | 2002-04-26 | 2003-11-10 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| EP1536814A4 (en) * | 2002-07-03 | 2006-02-15 | Immunogen Inc | ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF |
| EP1660535A2 (en) | 2002-11-27 | 2006-05-31 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20060173171A1 (en) | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| DE602005018325D1 (de) | 2004-02-19 | 2010-01-28 | Genentech Inc | Antikörper mit korrigierten cdr |
| JP4088655B2 (ja) | 2004-09-06 | 2008-05-21 | キリンファーマ株式会社 | 抗ａ３３抗体 |
| RU2418004C2 (ru) | 2004-10-04 | 2011-05-10 | Дженентек, Инк. | Модуляторы активатора фактора роста гепатоцитов |
| EP2526957A3 (en) | 2005-03-30 | 2013-02-20 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
| EP1904531B1 (en) | 2005-07-08 | 2010-10-06 | Pfizer Limited | Madcam antibodies |
| US7825092B2 (en) | 2006-08-08 | 2010-11-02 | University Of South Florida | Dendroaspis natriuretic peptide for treatment of cancer |
| US20090075926A1 (en) | 2006-12-06 | 2009-03-19 | Bamdad Cynthia C | Method for identifying and manipulating cells |
| US8420591B2 (en) | 2006-12-08 | 2013-04-16 | Dana-Farber Cancer Institute, Inc. | MUC1 and galectin-3 |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| PT2520590T (pt) * | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| EP2145901B1 (en) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Recombinant anti-MUC1 antibodies |
| CN102239182B (zh) | 2008-10-06 | 2014-07-09 | 米纳瓦生物技术公司 | Muc1*抗体 |
| KR20160017117A (ko) | 2008-10-09 | 2016-02-15 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| CN102264765B (zh) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| JP5549848B2 (ja) | 2008-12-25 | 2014-07-16 | 東ソー株式会社 | ルテニウム化合物、その製法及びそれを用いた成膜法 |
| KR20210019599A (ko) | 2009-06-11 | 2021-02-22 | 미네르바 바이오테크놀로지 코포레이션 | 줄기세포 및 전구세포를 배양하는 방법 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| AU2011288412A1 (en) * | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
| CN109456932A (zh) * | 2011-10-17 | 2019-03-12 | 米纳瓦生物技术公司 | 用于干细胞增殖和诱导的培养基 |
| WO2013157102A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CN104995518A (zh) * | 2012-07-24 | 2015-10-21 | 米纳瓦生物技术公司 | Nme变体物种表达和抑制 |
| WO2014028668A2 (en) | 2012-08-14 | 2014-02-20 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| JP6571527B2 (ja) | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | 二重特異性抗体 |
| AU2014218872A1 (en) | 2013-02-20 | 2015-10-08 | Minerva Biotechnologies Corporation | NME inhibitors and methods of using NME inhibitors |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| KR102448454B1 (ko) * | 2014-01-29 | 2022-09-28 | 다나-파버 캔서 인스티튜트 인크. | Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체 |
| CN103880956B (zh) | 2014-03-10 | 2015-12-30 | 中国人民解放军第四军医大学 | 抗muc1单克隆抗体及其轻链和重链可变区 |
| KR20210107166A (ko) | 2014-04-07 | 2021-08-31 | 미네르바 바이오테크놀로지 코포레이션 | 항-ｎｍｅ 항체 |
| WO2015166056A1 (en) | 2014-05-02 | 2015-11-05 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| US10865243B2 (en) * | 2014-07-16 | 2020-12-15 | Hinrich Abken | Chimeric antigen receptor and its use |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| AU2016219350A1 (en) | 2015-02-10 | 2017-08-24 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
| CN109312954B (zh) | 2016-02-17 | 2020-10-16 | 齐鲁工业大学 | 一种等离子体加热器 |
| EP3525804A4 (en) * | 2016-10-11 | 2020-09-09 | Minerva Biotechnologies Corporation | HUMANIZED ANTI-MUC1 * ANTIBODIES AND USE OF THE CLIVING ENZYME |
| US20200390870A1 (en) * | 2017-11-27 | 2020-12-17 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| CN120484122A (zh) * | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
-
2016
- 2016-02-10 AU AU2016219350A patent/AU2016219350A1/en not_active Abandoned
- 2016-02-10 CN CN201680021263.8A patent/CN107660213B/zh active Active
- 2016-02-10 CA CA2976089A patent/CA2976089A1/en active Pending
- 2016-02-10 US US15/549,942 patent/US11746159B2/en active Active
- 2016-02-10 EP EP16749836.9A patent/EP3256494A4/en active Pending
- 2016-02-10 CN CN202211743245.4A patent/CN116199790A/zh active Pending
- 2016-02-10 JP JP2017542004A patent/JP6895890B2/ja active Active
- 2016-02-10 WO PCT/US2016/017422 patent/WO2016130726A1/en not_active Ceased
-
2017
- 2017-08-08 IL IL253909A patent/IL253909B/en unknown
-
2021
- 2021-02-15 JP JP2021021535A patent/JP7324789B2/ja active Active
- 2021-10-21 AU AU2021254602A patent/AU2021254602B9/en active Active
-
2022
- 2022-08-04 US US17/817,515 patent/US11897967B2/en active Active
- 2022-08-04 US US17/817,525 patent/US12006371B2/en active Active
-
2023
- 2023-07-31 JP JP2023124894A patent/JP2023162180A/ja active Pending
-
2024
- 2024-04-24 US US18/644,795 patent/US20250026853A1/en active Pending
- 2024-09-18 AU AU2024219825A patent/AU2024219825A1/en active Pending
-
2025
- 2025-05-30 JP JP2025091489A patent/JP2025148326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512379A5 (OSRAM) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2019535670A5 (OSRAM) | ||
| JP2019536470A5 (OSRAM) | ||
| HRP20240959T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1 | |
| JP2019201643A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2018520993A5 (OSRAM) | ||
| JP2015163068A5 (OSRAM) | ||
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| JP2013198490A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2017149720A5 (OSRAM) | ||
| JP2017052784A5 (OSRAM) | ||
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| JP2017500057A5 (OSRAM) | ||
| JP2020514277A5 (OSRAM) | ||
| JP2014205674A5 (OSRAM) | ||
| JP2016505546A5 (OSRAM) | ||
| KR20220110539A (ko) | 치료 및 진단용 신규 분자 |